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DISCUSSION
Dr George Andros (Encino, Calif). I would like to congratu-
late you not only for presenting a wonderful series but also for
coming to us with 10-year clinical and hemodynamic data. That is
something we must encourage from our colleagues who favor
endovascular techniques and I applaud you for doing that.
I have two questions. In view of the fact that 20% of your patients
developed contralateral occlusive disease after they had an aorto or
iliofemoral bypass, would you recommend that the patients with
extensive unilateral iliac disease undergo primary aortobifemoral by-
pass and thereby solve the problem once and forever?
Second, since the patients with compromised outflow on the
recipient side did less well, would you recommend that they are
watched more closely with a low threshold for receiving a distal
bypass graft? Not only would this policy relieve symptoms but also
preserve the cross femoral bypass.
Dr Jean-Baptiste Ricco. Concerning your first question and
looking at the results of our study, you may be right, however, at
the present time, we will certainly proceed first with an iliac
recanalization or a hybrid procedure with iliac recanalization and
femoral reconstruction. If this does not work, we will then certainly
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consider a bilateral revascularization particularly if the life expect-
ancy of the patient is high. Concerning the femoral outflow,
occlusion or significant stenosis of the SFA in the recipient leg was
associated in our study with a significantly lower patency after
crossover bypass but not after direct bypass, and we will certainly
recommend in these cases a distal revascularization to enhance
patency of the crossover bypass.
Dr Vikram Kashyap (Cleveland, Ohio). Two questions. One,
in our series, looking at endovascular recanalization of iliac occlu-
sions, 30% of groin vessels needed either an endarterectomy or a
profundaplasty. Is that similar in your series?
Second, when this study started 20 years ago, all of these
patients were excluded from endovascular techniques that were
deemed not feasible. But in the end, if I understood correctly,
approximately 16% ended up getting an angioplasty on the ipsilat-
eral iliac artery. Have endovascular techniques changed your ap-
proach to iliac occlusions?
Dr Jean-Baptiste Ricco. Concerning your first question, we
have the same experience, in this series, 52 out of 143 patients
(36%) had a profundaplasty with or without a femoral endarterec-
tory. Considering your second question, we did 12 angioplasties of
the donor iliac artery in the crossover group mainly for TASC A or
B lesions that developed some years after construction of the
crossover bypass. In the direct bypass group, 14 patients (20.2%)
developed significant stenosis of the contralateral iliac artery re-
quiring angioplasty in six and crossover bypass in two. Our practice
has certainly changed in the last 10 years. Not surprisingly, endo-
vascular techniques can provide excellent long-term results in
selected iliac artery lesions and have also improved the outcome of
crossover femoral bypass in patients with suboptimal donor iliac
artery.
Dr Subodh Arora (Washington, DC). I noticed that quite a
number of patients in the iliofemoral group, you used the trans-
peritoneal approach. Was there any particular reason why that
approach was used over the retroperitoneal?
Dr Jean-Baptiste Ricco. Two different techniques were used in
the direct bypass group: 36 patients had an aortofemoral bypass
and 33 patients had a common iliac-femoral bypass. Forty-three
patients had a retroperitoneal approach and 26 patients had a
transperitoneal approach. All direct iliofemoral bypasses and 10
aortofemoral bypasses were approached by a retroperitoneal route.
Transperitoneal route was used exclusively in the remaining 26
patients with an aortafemoral bypass. In this study, the choice of
the operative technique was left to the discretion of the surgeon.
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